Farallon Capital Management LLC purchased a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 4,000,000 shares of the company's stock, valued at approximately $12,360,000. Farallon Capital Management LLC owned about 3.72% of Tango Therapeutics at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of TNGX. TCG Crossover Management LLC purchased a new position in shares of Tango Therapeutics during the 4th quarter worth $33,174,000. Boxer Capital Management LLC purchased a new position in shares of Tango Therapeutics during the 4th quarter valued at $32,077,000. Gilead Sciences Inc. purchased a new position in shares of Tango Therapeutics during the 4th quarter valued at $15,000,000. Nantahala Capital Management LLC purchased a new position in shares of Tango Therapeutics during the 4th quarter valued at $8,666,000. Finally, Blue Owl Capital Holdings LP purchased a new position in shares of Tango Therapeutics during the 4th quarter valued at $5,352,000. Hedge funds and other institutional investors own 78.99% of the company's stock.
Analyst Ratings Changes
Separately, HC Wainwright restated a "buy" rating and set a $13.00 target price on shares of Tango Therapeutics in a research note on Monday, April 14th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $12.33.
View Our Latest Research Report on Tango Therapeutics
Tango Therapeutics Stock Performance
NASDAQ:TNGX traded up $0.02 during midday trading on Friday, reaching $1.12. 467,242 shares of the stock traded hands, compared to its average volume of 1,079,341. Tango Therapeutics, Inc. has a 12-month low of $1.03 and a 12-month high of $12.02. The business has a 50-day moving average of $1.51 and a two-hundred day moving average of $2.66. The stock has a market capitalization of $121.08 million, a PE ratio of -0.95 and a beta of 1.02.
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. The company had revenue of $4.12 million for the quarter, compared to analyst estimates of $7.84 million. Research analysts anticipate that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current year.
About Tango Therapeutics
(
Free Report)
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
See Also
Before you consider Tango Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tango Therapeutics wasn't on the list.
While Tango Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
